Pergolide-induced pleuropulmonary fibrosis

被引：21

作者：

Bleumink, GS

van der Molen-Eijgenraam, M

Strijbos, JH

Sanwikarja, S

van Puijenbroek, JP

Stricker, BHC

机构：

[1] Inspectorate Healthcare, Drug Safety Unit, NL-2500 BC The Hague, Netherlands

[2] Erasmus Univ, Ctr Med, Pharmacoepiemiol Unit, Dept Internal Med & Epidemiol & Biostat, Rotterdam, Netherlands

[3] Nij Smellinghe, Dept Pulm Dis, Drachten, Netherlands

[4] De Tjongerschans Hosp, Dept Pulm Dis, Heerenveen, Netherlands

来源：

CLINICAL NEUROPHARMACOLOGY | 2002年 / 25卷 / 05期

关键词：

pergolide; pleural fibrosis; pulmonary fibrosis;

D O I：

10.1097/00002826-200209000-00013

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Pleuropulmonary fibrosis is a rare, but well-recognized adverse effect of ergot alkaloids. We report on four patients who developed pleural and/or pulmonary fibrosis during treatment with pergolide and give characteristics of 87 cases with one or more symptoms of serosal fibrosis. Retroperitoneal and pleuropulmonary fibrosis are serious conditions, which are often irreversible after drug withdrawal. Increased awareness may help to diagnose these complications at an earlier stage and to minimize any permanent damage to the patient.

引用

页码：290 / 293

页数：4

共 9 条

[1]

[Anonymous], 1996, HOUDINI FX

[2] Pleuropulmonary disease due to pergolide use for restless legs syndrome [J].